报价延迟最少15分钟:2025/09/05 22:11 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.14/-1.30
|
|
企业价值
77.90M
|
| 资产负债 |
|
每股账面净值
1.81
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/05 22:11 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders. |
